The immediate-early gene Arc is a master regulator of synaptic function and a critical determinant of memory consolidation. Arc protein is localized to excitatory synapses, where it controls AMPA receptor endocytosis, and to the nucleus, where it associates with Tip60, a subunit of a chromatin modifying complex. Here we show that Arc interacts with dynamic chromatin loops and associates with histone markers for active enhancers and transcription in cultured hippocampal neurons. When Arc induction by pharmacological network activation was prevented using a short hairpin RNA, the expression profile was altered for over 1900 genes. Many gene families were affected by the absence of Arc, most notably those associated with synaptic function, neuronal plasticity, intrinsic excitability (channels, receptors, transporters), and signaling pathways (transcription factors/regulators). Interestingly, about 100 genes whose activitydependent expression level depends on Arc are associated with the pathophysiology of Alzheimer's disease, suggesting a critical role for Arc in the development of neurodegenerative disorders. When endogenous Arc expression was induced in a non-neuronal cell line (HEK293T), the transcription of many neuronal genes was increased, suggesting Arc can control expression in the absence of activated signaling pathways. Taken together, these data establish Arc as a master regulator of neuronal activity-dependent gene expression and a significant factor underlying the pathophysiology Alzheimer's disease.
INTRODUCTION
The neuronal immediate-early gene Arc 1,2 plays a critical role in memory consolidation [3] [4] [5] [6] . Arc expression is rapidly and transiently induced by novel behavioural and sensory experiences [7] [8] [9] [10] [11] , while its mRNA is enriched in dendrites and targeted to recently activated synapses, where it is locally translated 12, 13 . Arc protein resides in excitatory synapses, where it controls AMPA receptor endocytosis 14 , allowing it to act as a master regulator of synaptic function and plasticity 15, 16 that implements homeostatic synaptic scaling at the neuronal network level [17] [18] [19] . While the synaptic role of Arc has been well documented, the observed failure to convert early-to late-LTP in Arc knockout mice cannot be explained by an AMPA receptor endocytosis deficit 4 . This suggests that Arc may have additional functions. Interestingly, Arc protein can also be localized in the nucleus, where it binds to a beta-spectrin IV isoform and associates with PML bodies [20] [21] [22] , sites of epigenetic regulation of gene transcription 23 . Nuclear Arc has been reported to regulate transcription of the GluA1 AMPA receptor 24 . Recently, another nuclear function for Arc has been demonstrated: Arc interacts with the histone-acetyltransferase Tip60 25 , a subunit of a chromatin modifying complex [26] [27] [28] . Arc expression level correlates with the acetylation status of one of Tip60's substrate: lysine 12 of histone 4 (H4K12) 25 , a memory-associated histone mark which declines with age 29 . These newly discovered nuclear functions may point to an epigenetic role for Arc in memory consolidation. We have therefore investigated Arc's interaction with chromatin and its association with histone marks in cultured hippocampal and cortical neurons. Fluorescent microscopy experiments demonstrated a highly dynamic interaction between chromatin and Arc, as well as a tight association between Arc and histone marks for active enhancers and active transcription. RNA-Sequencing (RNA-Seq) experiments in which activity-dependent Arc expression was prevented using a short hairpin RNA showed that Arc regulates the transcription of over nineteen hundred genes controlling memory, cognition, synaptic function, neuronal plasticity, intrinsic excitability and intracellular signaling. Interestingly, Arc also controls the expression of susceptibility genes for Alzheimer's disease, as well as many genes implicated in the pathophysiology of this disorder. A Gene Ontology (GO) analysis identified downstream signaling pathways and diseases associated with the observed changes in mRNA levels, while an Ingenuity Pathway Analysis (IPA) revealed upstream regulators predicted by the change in gene expression profile caused by Arc knockdown. Finally, we induced expression of Arc in human embryonic kidney 293T (HEK-293T) cells, using CRISPR-Cas9, which resulted in the increased transcription of many neuronal genes. Taken together, our data demonstrate that Arc controls neuronal activity-dependent expression of many genes underlying higher brain functions and may be involved in the development of Alzheimer's disease (AD) and other neurodegenerative disorders.
Arc associates with dynamic chromatin. The interaction between Arc and chromatin was studied in more detail using time-lapse fluorescence microscopy of hippocampal neurons expressing Arc and histone 2B (H2B) tagged with YFP and mCherry, respectively ( Fig. 3) . Arc was induced in 18 days in vitro (DIV) hippocampal neurons by a 4-hour treatment with 4BF. The time-lapse movies of Arc-eYFP and H2B-mCherry revealed a highly dynamic chromatin that constantly reorganizes on a time scale of seconds (Movie 1). Arc is concentrated in small puncta to which the chromatin can be seen to reach out with finger-like structures, which likely represent the dynamic chromatin loops described by others [53] [54] [55] .
Arc associates with a marker of active enhancers. Because Arc was shown to associate with the Tip60 substrate H4K12Ac 25 , we have examined interactions of Arc with other histone modifications, by comparing Arc-positive and -negative neurons following pharmacological network activation. The 'histone code' 56 is complex and still incompletely understood. We have therefore focused on histone modifications whose function is best studied. In our survey we have found several histone modifications for which there was a difference in nuclear organization between Arc positive and negative neurons, including H3K9Ac, H3K4me3, and H3K14Ac (data not shown). Figure 4 illustrates the close association between Arc and H3K27Ac, which marks active enhancers 57, 58 . Arc and H3K27Ac form two separate lattice-like structures that are closely inter-connected and, in some locations, appear to overlap (yellow areas in Figure 4 ). Arc associates with a marker for active transcription. Another histone mark that showed a strong interaction with Arc was H3K9Ac-S10P, which requires the concurrent acetylation of lysine 9 of histone H3 (H3K9Ac) and phosphorylation of the neighboring serine 10 (S10P). This dual marker indicates genomic regions undergoing active transcription 22, 59, 60 . Figure  5 illustrates the close interaction between Arc and this histone mark, using Stochastic Optical Reconstruction Microscopy (STORM), a form of super-resolution microscopy with a resolution of ~30 nm 61 . Both Arc and H3K9Ac-S10P are enriched at the nuclear periphery, where reorganization of chromatin between active and inactive transcriptional states takes place 62, 63 . With the increased resolution of STORM, Arc can be seen to localize to distinct puncta. H3K9Ac-S10P forms an elaborate meshwork, as expected for chromatin, but also is enriched in puncta-like domains. Arrowheads in Figure 5A indicate the close apposition between these two sets of puncta. Close inspection of the interface between the two types of puncta revealed invasions of H3K9Ac-S10P into the Arc puncta (arrows in Fig. 5B) , resembling the finger-like chromatin loop structures seen in live cell imaging (Fig. 3, Movie) .
Arc regulates activity-dependent gene transcription. Because Arc was found to associate with histone marks involved in transcription activation, we wanted to investigate whether network activity-induced Arc expression alters the gene expression profile of the neurons. Four short hairpin RNAs (shRNAs) targeting the coding region of Arc were tested for their ability to suppress Arc induction following four hours of 4BF treatment. We selected the most effective shRNA to generate an adeno-associated AAV9 virus. Because AAV9 infection itself may alter the gene expression profile, we also generated a negative control consisting of AAV9 virus encoding a scrambled version of the Arc shRNA. We performed an RNA-Seq analysis of cortical neurons expressing either the Arc shRNA or its scrambled control. When 4BF-mediated Arc expression is prevented using the Arc shRNA ( Fig. 6A) , mRNA levels for more than 1900 genes were altered (Fig. 6B) . Many gene families were affected, including those associated with plasticity genes (Jun, Fosb, Bdnf, Dlg4, Egr4, Npas4 and Nr4a1), synaptic proteins (syntaxin Stx12 and synaptotagmin Syt3), neurotransmitter receptors (NMDA, AMPA, GABA, glycine, serotonin and metabotropic glutamate receptors) ( Fig.  6B) . Arc also regulated the expression of genes controlling intrinsic excitability: 62 genes encoding ion channels (20 K + , 4 Na + , and 9 Ca 2+ channel subunits, 7 transient receptor potential (Trp) channels, 14 ligand-gated ion channels, 7 regulatory subunits and 1 non-selective cation channel), and 139 genes encoding transporters/pumps (for glutamate, GABA, serotonin, ADP, ATP, phosphate, glucose, inositol, alanine, cysteine, glutamine, glycine, proline, Na + , Ca 2+ , Cl -, H + and Zn 2+ ). These results suggest that Arc regulates activity-dependent gene expression relevant for synaptic function, neuronal plasticity and intrinsic excitability. Table 1 shows the 30 top-ranking genes sorted by absolute fold change (FC) caused by the shRNA-mediated knockdown of Arc expression. Gene names are shown together with a description of their function, their Fold Change, False Discovery Rate (FDR), and references to relevant papers. Many of the top-regulated genes are involved in synapse modulation, neurotransmission, neurogenesis and neurological disorders. Interestingly, 9 out of the top 30 genes have been implicated in the pathophysiology of AD (Fgf1, Slc30a4, Npas4, Cxcl1, Jdp2, Nts, Mmp10, Orai2 and Tomm34) while an additional 5 genes are linked to amyloid beta (Aβ) metabolism (Mmp13, Mmp12, Slc2a13, Igf1r and Apba1).
GO analysis of differentially expressed genes.
A Gene Ontology (GO) analysis of the RNA-Seq data identified several biological processes and molecular functions that were affected when Arc expression was prevented during network activation ( Fig. 7 ). Arc knockdown altered many genes involved in the regulation of nervous system development and neuronal differentiation ( Fig. 7A ). In addition, many of the genes were enriched in biological processes involved in cognition, regulation of cell projection organization and axonogenesis ( Fig. 7A) , processes which could modulate structural plasticity involved in neural development, learning and memory 64,65 . While the top ten regulated genes enriched for the regulation of plasma membrane bounded cell projection organization were both up-and down-regulated ( Fig. 7Cii) , genes enriched for cognition and the regulation of axonogenesis were mostly down-regulated due to the absence of Arc ( Fig. 7Ci and iii). Many of the altered genes were also enriched in molecular functions such as ion channel regulator activity, glutamate receptor binding and ligand-gated ion channel activity ( Fig. 7B) , including Sgk1 (Fig. 7Di) , Dlg4, which encodes PSD-95 ( Fig.  7Dii) , and Grin2c, which encodes the NMDA receptor NR2C subunit( Fig. 7Diii) . These molecular functions are well-established to underlie synaptic plasticity processes crucial for formation of memory 66,67 .
Arc regulates expression of synaptic and plasticity genes.
From the GO results in Figure 7 , we observed that the knockdown of Arc affected many genes involved in synaptic plasticity, as well as genes implicated in processes underlying learning and memory. We have therefore investigated how Arc knockdown affected genes encoding synaptic proteins by manually curating a list of differentially expressed genes whose protein products are located at the presynaptic or postsynaptic compartment. A total of 232 synaptic genes were differentially expressed. These genes are involved in the development and growth of axons and dendrites, including Ephb3, Lrfn2, Lama5, Neurod2, Sema4f, Caprin2, and Unc5c and the modulation of the synapses and dendritic spines, including Npas4, Pcdh8, Ephb3, Lrfn2, Bdnf, Atxn1, Cbln2, Cadps2, Caprin2, C1ql1, C1ql3, and Unc5c ( Table 2 ). Many of these synaptic genes are also involved in neuroplasticity, cognition, learning and memory, including Syt3, Pcdh8, Pdyn, Lrfn2, Dlg4, Kcna4, Bdnf and Mapki8ip2. Figure 8 lists neuroplasticity genes and genes that are involved in cognition, learning and memory whose activity-dependent expression is regulated by Arc. Most of these genes were down regulated when activitydependent Arc expression was prevented.
Arc knockdown altered synaptogenesis, synaptic plasticity and neuroinflammation pathways. From the GO results and the list of manually curated synaptic genes, we were interested in investigating the signaling pathways and the possible downstream effects resulting from Arc knockdown. We have analyzed the differentially expressed genes and their respective fold changes using IPA. Figure 9A shows the top 15 pathways that were altered due to Arc knockdown. IPA made inferences on the activation or inhibition of the pathways based on the differential expression observed and canonical information stored in the Ingenuity Knowledge Base. The degree of activation or inhibition of each identified pathway is indicated by the z-score. The ratio is calculated as the number of differential expressed genes for each pathway divided by the total number of genes involved in that pathway. Many identified pathways involved cellular signaling cascades, including those mediated by CDK5, PTEN, integrin and corticotropin releasing hormone (Fig. 9A) . Pathways predicted to be responsible for the observed differential expression profile include opioid and endocannabinoid signaling, synaptogenesis, synaptic long-term depression (LTD) and neuroinflammation ( Fig. 9A  and 9B) . Kcnj5, Ptgs2, Grin2c, Cacng4 and Gnaq are members of at least two of the pathways shown and are synaptic genes or associated with cognition ( Fig. 7, 8 , 9A, Table 2 ). Except for the neuroinflammation signaling pathway, all these pathways are associated with synaptic plasticity. Knockdown of Arc modulated neurotransmission, synaptic plasticity, spine formation/maintenance and neurite outgrowth, processes that are crucial for learning and memory ( Fig. 9B ) [68] [69] [70] . Interestingly, the two hallmarks of AD, the generation, clearance and accumulation of amyloid beta (Aβ) and the formation of neurofibrillary tangles (NFTs), are both affected by downregulation of the neuroinflammation signaling pathway resulting from Arc knockdown ( Fig. 9B) . These alterations in the generation and clearance of molecular markers and triggers of AD could indicate a possible role of Arc in the pathophysiology of AD 71 .
Arc knockdown changes the expression of genes involved in the aetiology and pathophysiology of AD.
Considering that the generation, clearance and accumulation of amyloid beta and neurofibrillary tangles was predicted to be altered due to the knockdown of Arc, we investigated whether any neurological diseases or psychological disorders were correlated with the profile of differentially expressed genes mediated by Arc knockdown. Table 3 summarized the disease annotation and predicted activation state for two disease/disorder classes whose associated genes were significantly altered by Arc knockdown. Absence of Arc was predicted to increase damage of the cerebral cortex and its neurons and cells. In addition, Arc knockdown was also associated with psychological disorders, including Huntington's Disease, basal ganglia disorder, central nervous system (CNS) amyloidosis, tauopathy and Alzheimer disease. Of note, CNS amyloidosis and tauopathy are predictors of AD. The activation states of the five psychological disorders were not reported, possibly due to inconsistencies in the literature findings with respect to fold changes of the differentially expressed genes. However, the p-values for all five disorders were highly significant, suggesting that the progression of these disorders may be modulated by the Arc function.
We next investigated how Arc knockdown could affect genes that were previously identified to increase susceptibility to AD. We have manually curated genes that were found to be genetic risk factors of AD and validated them by referencing the Genome Wide Associations Studies (GWAS) catalogue 72 . Notably, critical genetic risk factors of AD such as Picalm, Apoe, Slc24a4, and Clu were downregulated upon the knockdown of Arc [73] [74] [75] [76] [77] (Fig. 10) . Out of a total of 39 susceptibility genes identified, 26 were regulated by Arc ( Fig. 10) .
Because Arc plays a role in the aetiology of AD by modulating its genetic risk factors, we investigated if Arc regulates genes that are more broadly involved in the pathophysiology of AD. Table 4 lists the results. While some differentially expressed genes control amyloid beta formation/accumulation through the regulation of cleavage and stabilization of amyloid precursor protein (APP) (Mmp13, Slc2a13, Apba1, Casp8, Ptgs2, Gpr3, Pawr, Timp3, Kcnip3, Plk2, Aplp2, Bace2, Apoe and Apba2), others are involved in the hyperphosphorylation of tau and formation of neurofibrillary tangles (Npas4, Cxcl1, Dryrk2, Tril, Pltp, Plk2 and Selenop). Arc knockdown also altered the expression of genes that are associated with the neurodegeneration and neurotoxicity observed in AD (Casp8, Bcl2l11, Alg2, Tac1, Bdnf, Hmox1, Pawr, Ccl2, Selenop and Atf6). Finally, Arc regulated genes associated with altered cognitive function, a characteristic of AD (Mmp13, Pdyn, Tac1, Bdnf, Nr4a2, Penk, Pltp and Ccl2). To date, presenilin 1 (Psen1) and glycogen synthase kinase 3 beta (Gsk3b) are the only AD mediators which have been reported to physically associate and interact with Arc [78] [79] [80] . Arc also interacts with endophilin 2/3 and dynamin and recruits them to early/recycling endosomes to traffic APP and beta secretase 1 (BACE1), crucial determinants of AD progression 80 . However, the observation that knocking down Arc resulted in more than 100 differentially expressed genes that are either AD susceptibility genes or genes implicated in the pathophysiology of AD ( Fig. 10 and Table 4 ), indicated that Arc could be mediating the expression of these genes via transcriptional regulation and not simply physical interactions. Arc has previously been reported to reside in the nucleus 20,24,30,31 and we have shown how Arc physically associates with chromatin and with markers of active transcription and enhancers ( Fig. 3, 4 and 5). Therefore, we wanted to investigate how Arc downregulation affects transcription regulation.
Arc regulates the expression of transcription factors. From our GO analysis and a manual curation based on literature citations, we have identified 369 transcriptional regulators and transcription factors whose expression is controlled by Arc. Table 5 shows the top 40 transcriptional regulators or factors whose mRNA levels were altered when activity-dependent Arc expression was prevented. Some of the transcriptional regulators are involved in neuronal development and differentiation (Fgf1, Tgfb1i1, Fezf2, Jun, Magel2, Neurod2, Atxn1, Gdf15, Prdm1, Mycn, Nr4a2 and Pou2f2), while others are involved in the development of neurological or neurodegenerative diseases (Npas4, Igf1r, Txnip, Lgr4, Cebpd, Pim1, Magel2, Ireb2, Smad7, Sorbs1, Nfil3, Pknox2, Hdac9, Hmox1, Atxn1, Cbfb, Lrp2, Hipk3 and Nr4a2). Many of the transcriptional regulators/factors have been implicated in memory formation and plasticity, such as such as Thbs1, Jun, Tet3, Fosb, Atxn1 and Cbfb. A GO analysis by DAVID 81 was carried out to identify the biological processes that these transcription factors could be modulating. Table 6 shows the top 20 biological processes that were regulated by altered transcription factor expression and that have neurological relevance. Corroborating the identified functions of the top 40 transcriptional regulators/factors ( Table 5) , differentially expressed transcriptional regulators/factors were observed to be highly enriched in biological processes such as differentiation of neurons, nervous system development, learning, long-term memory and aging ( Table  6 ). Some of the transcriptional regulators were involved in multiple processes: Npas4, Jun, Bdnf, Nr4a2 and Elavl4 modulate learning, long-term memory, aging, neuron differentiation and nervous system development ( Table 6 ).
Upstream regulators associated with Arc-dependent genes.
Because Arc knock down resulted in the differential expression of 1945 genes ( Fig. 6) , altering downstream pathways ( Fig. 9 ) possibly leading to disease states ( Table 3) , we identified the upstream modulators that could explain the vast differential expression pattern observed. From the IPA analysis, 11 upstream regulators were predicted to critically contribute to the differential expression profile ( Table 7) . Except for Sox2, none of these upstream regulators were transcriptionally affected by Arc knockdown, suggesting Arc controls their function through a different mechanism. SOX2 and HDAC4 were both activated by the absence of Arc, while the function of the remaining 9 regulators was inhibited. Of note, the predicted inhibition of CREB1 (z-score = -3.5) and APP (z-score = -2.8) explains the differential expression of 100 and 94 genes, respectively ( Table 7) . The 11 upstream regulators predicted by IPA control the expression of Nr4a2, Slc6a1 and Igf1r, genes that are also involved in AD progression, neuroinflammation pathways and synaptic LTD ( Fig. 9A and Table  4 ). We have investigated the mechanisms by which Arc could alter the function of the identified upstream regulators resulting in the alteration of downstream pathways and AD progression. The downstream pathways investigated are (i) opioid signaling, (ii) synaptogenesis signaling, (iii) the endocannabinoid neuronal synapse pathway, (iv) synaptic LTD and (v) neuroinflammation signaling (Fig 11) . These are also the pathways whose downstream effects we focused on in Figure 9 . APP, CREB1 and TNF are three upstream regulators identified by IPA that controlled the highest number of genes involved in the downstream pathways highlighted (Fig. 11) . The top five genes regulated by APP were Igf1r (synaptic LTD) 82 , Ptgs2 (endocannabinoid neuronal synapse pathway; neuroinflammation, AD progression) [83] [84] [85] [86] , Jun (neuroinflammation, AD progression) [87] [88] [89] [90] , Dlg4 (PSD95, synaptogenesis) 91, 92 and Syn2 (synaptogenesis) 93 (Fig. 11) . In addition to Ptgs2 and Syn2, CREB1 regulated the differential expression of Slc6a1 (neuroinflammation) 94 , Pdyn (opioid signaling) 95 and Fosb (opioid signaling) 96 (Fig. 11) . Interestingly, TNF, whose transcription was not altered upon knockdown of Arc, regulates 15 genes (Table 7) , the top five of which are Casp8 (neuroinflammation) 97 , Ptgs2 (also regulated by APP and CREB1), Gabrg2 (neuroinflammation) 98, 99 , Bdnf (synaptogenesis; neuroinflammation, AD progression) [100] [101] [102] [103] and Penk (opioid signaling, AD progression) 104 . While the top CREB1-regulated genes are mainly associated with the opioid signaling pathway, APP and TNF are implicated in neuroinflammation. Triggering of the neuroinflammation pathway leads to the altered expression of AD-associated genes such as Ptgs2, Jun, Bdnf, Hmox1 and Gabbr2.
Arc over-expression alters gene expression in human embryonic kidney cells. The results presented thus far suggest that preventing Arc expression during neuronal network activation results in an altered gene expression profile affecting synaptic plasticity and cellular excitability, as well as neurodegenerative disease state. We therefore tested whether Arc can alter gene transcription, outside the context of neuronal network activation and without viral infection. We induced the expression of the endogenous Arc gene in human embryonic kidney (HEK293T) cells using a CRISPR-Cas9 approach 105 ( Fig. 12A) . Whereas wildtype HEK293T cells expressed Arc at a very low level, targeting a transcription activator complex to its promoter increased Arc mRNA levels nearly 250-fold. This in turn altered the expression of 57 genes (absolute FC > 2, p < 0.05), with 54 genes up-regulated and 3 genes downregulated. Many of the genes have neuronal functions ( Fig.  12B) . We have performed a GO analysis to understand the cellular components ( Fig. 12C ) and biological processes ( Fig.  12D ) these differentially expressed genes were involved in. We observed many genes that are typically expressed in neurons or are synaptic components, as indicated by the following GO terms: i) synapse part (p = 1.1E-04), ii) presynapse (p = 1.0E-03), iii) neuron part (p = 1.5E-03) and iv) postsynaptic membrane (p = 2.3E-03) ( Fig. 12C) . Differentially expressed genes upon the induction of Arc in HEK293T cells are involved in synaptic transmission processes or neuronal development, including i) chemical synaptic transmission (p = 2.5E-04), ii) signal release from synapse (p = 1.9E-03), iii) interneuron precursor migration (p = 3.2E-03) and iv) axon guidance (p = 3.2E-03) ( Fig. 12D) . Genes that are associated with these cellular components and processes were also highly altered, including i) Chat (p=4.7E-85, choline acetyltransferase) located at presynaptic terminals, synthesizes acetylcholine, ii) Oprd1 (p=2.6E-62, δ-opioid receptor), activation reduces pain and improves negative emotional states, iii) Arx (p=1.1E-70, Aristaless Related Homeobox), a transcription factor involved in neuronal migration and development, iv) Scn1b (p=6.6E-22, Na channel β1 subunit), involved in axonal guidance, v) Foxa3 (p=3.3E-24, Forkhead Box A3), a transcription factor involved in the determination of neuronal fate 106, 107 , vi) Pllp (p=1.5e-25, Plasmolipin), involved in membrane organization and ion transport, vii) Slc18a3 (p=1.6E-16), a vesicular acetylcholine transporter at the presynapse, viii) Fndc11 (p=4.4E-14, Fibronectin Type III Domain Containing 11), a vesicular gene, and ix) Adgrb1 (p=3.7E-12, Adhesion G Protein-Coupled Receptor B1), localized at the postsynapse, involved in synapse organization and cell projection morphogenesis ( Fig. 12B) .
Together with the results obtained with Arc knockdown in neurons, this finding strongly implicates Arc as a transcriptional regulator of neuronal development, synaptic function, plasticity and intrinsic excitability.
DISCUSSION
Activity-regulated cytoskeleton-associated protein (Arc) was discovered in 1995 as a neuronal activity-dependent immediate-early gene 1,2 , which is rapidly transcribed in response to network activation associated with novel experiences [7] [8] [9] [10] [11] . Knockdown of Arc expression interferes with stabilization of short-term memory, indicating that Arc plays a critical role in memory consolidation 3, 4 . Arc's function has been most widely studied in excitatory synapses, where it regulates endocytosis of AMPA receptors 14, 17 . Interestingly, AMPA receptor removal also underlies Aβ-induced synaptic depression and dendritic spine loss 108 , processes thought to be associated with cognitive dysfunction in Alzheimer's disease (AD) 109 . In Arc knockout mice, long-term potentiation (LTP) is not stable, and dissipates within a few hours, consistent with the impaired memory consolidation observed in these mice [3] [4] [5] [6] . However, the absence of the late form of LTP in Arc knockout mice cannot be explained by an AMPA receptor endocytosis deficit 4 , indicating that Arc must have additional functions. The data presented here identify a second function for Arc: regulation of neuronal activity-dependent transcription for genes associated with synaptic plasticity, intrinsic excitability and cellular signaling. Analysis of the differentially expressed genes points to Arc's involvement of several neurological disorders, including Autism, Huntington's and Alzheimer's disease. This newly proposed role for Arc is supported by its interaction with chromatin and histone markers reported here ( Fig. 2-5 , Movie).
Arc and chromatin.
Pharmacological network stimulation induces Arc in a subset of cultured neurons ( Fig. 1) . Whereas chromatin in cultured hippocampal neurons is relatively uniform, Arc positive neurons are characterized by a larger number of densely packed heterochromatin puncta (chromocenters), likely harbouring silent genes, interspersed with highly open euchromatin domains, which are capable of active transcription ( Fig. 2) . This result is consistent with what has been observed in vivo, where Arc-deficient mice were found to have decreased heterochromatin domains 31 . These significant changes in chromatin structure observed in Arc-positive neurons are likely associated with equally substantial alterations in gene expression profiles. The correlation between Arc expression and chromatin remodeling that we observed does not establish a causative relationship. It is possible that Arc expression requires an alteration in chromatin structure, or alternatively, Arc expression may cause chromatin remodeling. Additional experiments are needed to decide on the underlying mechanism. It is also not clear at this time what determines which neurons will express Arc following network activation, although it likely has to do with the degree of participation of individual neurons in the enhanced network activity, which in turn depends on their synaptic connectivity.
Arc appears to physically interact with DNA: timelapse movies show dynamic chromatin loops that appear to invade Arc puncta ( Fig. 3, Movie) . The interaction is transient, lasting only a few seconds. Because these Arc puncta likely contain the histone acetylase Tip60 25 , it is conceivable that this interaction alters chromatin accessibility, thereby facilitating transcription. This idea is further strengthened by the association of Arc puncta with a histone marker for active enhancers (Fig. 4) , as well as the close apposition between Arc puncta and puncta for a dual histone marker (H3K9Ac-S10P) that labels sites of active transcription ( Fig. 5) . A similar result has been obtained in vivo, where cocaine administration in rats results in an increase in nuclear Arc, which then associates with H3S10P 31 . Taken together, the data presented here on the interaction of Arc and chromatin may provide a mechanism for epigenetic regulation of gene transcription as the basis for memory consolidation.
How does Arc regulate transcription?
Preventing Arc induction during neuronal network activation affects the transcription of a very large number of genes ( Fig. 6) . The domain structure of Arc protein appears to rule out that it can function as a transcription factor 78 . This raises the question: how does Arc regulate transcription? One possible mechanism, discussed above, is that Arc epigenetically controls gene transcription by regulating chromatin structure (through Tip60 or other chromatin remodelers) and modification of histones (e.g. H4K12Ac 25 ). However, the differential gene expression associated with Arc knockdown is mediated through eleven upstream regulators identified by IPA (Table 7, Fig. 11 ). This suggests that Arc has additional, less direct ways of regulating transcription. Interestingly, to date, none of the eleven upstream regulator proteins have been shown to either directly interact with or be modulated by Arc. They are also not transcriptionally controlled by Arc (except for Sox2) ( Table 7) . How then does Arc regulate transcription by activating or inhibiting these upstream regulators? Using IPA and its Ingenuity Knowledge Base, we were able to identify several known interactors of Arc that can modulate the action of the upstream regulators, which could then subsequentially alter gene transcription ( Fig. 13A ). Next, we will discuss the mechanisms by which four identified Arc interactors, NOTCH1, TIP60/Kat5, APP and GSK3B, could modulate the upstream regulators. NOTCH1. NOTCH1 is a transmembrane receptor capable of signaling to the nucleus. Arc is required for the proteolytic cleavage of NOTCH1 to release its intracellular domain (NICD), which can translocate to the nucleus and alter transcription 110 . NICD regulates the expression of the transcriptional repressor BCL6 111 and the activity of the calcium-dependent kinase CAMK4 112 , which in turn alter the localization and the nuclear-cytoplasmic shuttling of the histone deacetylase HDAC4, thereby affecting its downstream interactions/modulation 113, 114 (Fig. 13B) . NOTCH1 could regulate the stability, nuclear localization and signaling of the transcription factor SOX2 through regulation of the protein kinase AKT1 and cell-surface glycoprotein CD44 [115] [116] [117] [118] (Fig. 13B) . NOTCH1, through NICD, controls the expression of plasminogen activator inhibitor-1 (SERPINE1) 119 , an inhibitor of thrombin (F2) 120 (Fig. 13B) . NOTCH1 regulates the transcriptional activity of T-cell factor 4 (TCF7L2) 121 , through its interaction with the DNA-repair protein Ku70 (XRCC6) 122 (Fig.  13B) . NOTCH1 interacts with the nerve growth factor NR4A1/Nur77 123 , thereby modulating expression levels of the cytokine tumor necrosis factor alpha (TNF) 124 . Finally, NOTCH1 regulates the expression level of the inhibitor of apoptosis protein cIAP1/Birc2 125 , which also affects TNF expression 126 (Fig. 13B) . TIP60/Kat5. The Kat5 gene encodes TIP60, a member of the MYST family of histone acetyl transferases, which plays important roles in chromatin remodeling and transcription regulation 127 . In the fruit fly Drosophila, TIP60 has been implicated in epigenetic control of learning and memory 128 , while it mediates APP-induced apoptosis and lethality in a fly AD model 129 . Nuclear Arc interacts with TIP60 at perichromatin regions and recruits TIP60 to PML bodies, sites of epigenetic transcription regulation 25 . Arc levels correlate with acetylation status of H4K12, a substrate of TIP60 and a memory mark that declines with aging 29 , suggesting that Arc mediates activation of TIP60. TIP60/Kat5 facilitates the repressive action of HDAC4 through the formation of complexes with the zinc-finger transcription factor KLF4 121,130 , the cAMP-dependent transcription factor ATF3 131-133 and the neurodegenerative disease protein ataxin-1 (ATXN1) 134,135 ( Fig. 13B) . Arc's interaction with TIP60/Kat5 may result in a complex being formed at the cIAP1/Birc2 promoter region 136 to mediate downstream signaling of TNF 126 (Fig. 13B) . TIP60/Kat5 forms a complex with the Kaiso transcription factor ZBTB33 137 resulting in the inhibition of the TCF7L2 transcriptional complex 138 (Fig. 13B) . Complexing of TIP60 with ARID1B could affect SOX2 signaling 139-141 . The regulation of SOX2 by TIP60/Kat5 could also have an implication on the transcriptional activity of Achaete-Scute homolog 1 (ASCL1), as SOX2 and ASCL1 regulate each other, possibly as a feedback loop 142,143 .
APP. The functional interaction between APP and Arc is crucial for Arc's modulation of upstream regulators (Fig. 13A) . Arc interacts with endophilin 2/3 (SH3GL3) and dynamin on early/recycling endosomes to alter the trafficking and localization of APP. The association of Arc with presenilin 1 (PSEN1) promotes the trafficking of γ-secretase to endosomes and enzymatic cleavage of APP 80 (Fig. 13B) . The generation of amyloid beta through APP cleavage leads to an altered downstream signaling, activity and production of HDAC4, SOX2 and F2 through changes of caspase-3 (CASP3) 144,145 , JUN 146, 147 and thrombospondin-1 (THBS1) 148, 149 , respectively ( Fig.  13B) . Cleavage of APP generates a cytosolic fragment, AICD, which forms a transcriptionally active complex with TIP60 and the transcription factor FE65 150 . AICD also modulates the ubiquitin-proteasome system (UPS) via UBE2N 151 , to change downstream signaling induced by TNF 152 (Fig. 13B) . The modulation of the UPS via UBE2N, UBC and UBE3A 153 could implicate the ubiquitination of serum-and glucocorticoid-regulated kinase-1 (SGK-1) [154] [155] [156] and polyglutamine-expanded ataxin 3 (ATXN3) 157 and their ability to regulate the transcription factor cAMP responsive element binding protein 1 (CREB1) 158, 159 (Fig. 13B) . The modulation of CREB1 would further implicate changes in expression levels of cAMP responsive element modulator CREM [160] [161] [162] (Fig. 13B) . Finally, APP has a role in the regulation of TNF through indirect modulation of CREM 163 and direct interactions with laminin could regulate the production of TNF 164, 165 (Fig. 13B) .
GSK3B. Although glycogen synthase kinase 3 beta (GSK3B)
is not regulated by Arc, promotion of cleavage of APP to amyloid beta enhances the induction and activation of GSK3B [166] [167] [168] . This could lead to modified downstream signaling of CREB1 169 (Fig. 13B) . GSK3B is also a downstream mediator of NOTCH1 170 , PSEN1 171 , and CAMK2B 172 , all of which are Arc interactors 80, 110, 173 . This creates an interesting situation as APP/amyloid beta is positively regulated by GSK3B 174, 175 , creating a positive feedback loop for amyloid beta production and its downstream signaling [166] [167] [168] (Fig. 13B) .
Interactions among TIP60, NOTCH1 and APP. A delicate regulatory network exists among Arc's interactors TIP60/Kat5, NOTCH1 and APP (Fig. 13B) . Arc's activation of the γ-secretase PSEN1 to promote cleavage of APP not only increases amyloid beta load, but also results in an increased level of the APP intracellular domain (AICD) 80, 176 . AICD forms a complex with TIP60/Kat5 to alter transcriptional activity crucial for AD progression 150, [177] [178] [179] [180] [181] [182] (Fig. 13B) . This AICD-TIP60 interaction is disrupted by NICD, formed when Arc activates NOTCH1 110 , thereby downregulating AICD signaling while promoting NICD signaling 183, 184 (Fig. 13B) . The formation of NICD and AICD is competitive, as NOTCH1 and APP are both substrates of γ-secretase 185 , whose activity is regulated by Arc 80 . In addition, the induction of TIP60 histone acetylation activity by Arc 25 could also increase the negative regulation of NOTCH1 183 (Fig. 13B ). This highlights Arc as an important modulator of the relationship and downstream signaling mediated by NOTCH1, TIP60/Kat5 and APP. Of note, the mRNA levels of Notch1, Kat5 and App were not significantly altered upon knockdown of Arc, indicating that the transcriptional changes brought about were due to protein interaction and activation ( Fig. 13B) , which is upstream of transcription ( Fig. 13A) . However, the modulation of upstream regulators by Arc is also dependent on the its subcellular localization.
Arc's subcellular localization determines its function.
When Arc is localized outside the nucleus it tends to accumulate in dendrites and spines, small membrane protrusions that harbour excitatory synapses. Here, Arc controls the removal of AMPA receptors by endocytosis, allowing it to regulate synaptic efficacy 14, 17 . Synaptic Arc also associates with the synaptic scaffolding protein PSD-95/Dlg4, which complexes with the tyrosine kinase FYN [186] [187] [188] , allowing it to regulate brain-derived neurotrophic factor (BDNF) signalling through tyrosine receptor kinase B (TrkB), a major pathway for synapse maturation, plasticity and neurodevelopmental disorders 189 . Activation of FYN could also mediate the secretion of TNF 190 (Fig. 13B) . A high-affinity interaction with calcium-calmodulin kinase 2 beta (CAMK2B) targets Arc to inactive synapses, where it removes GluA1 AMPA receptors from the postsynaptic membrane surface 173 .
Arc has been shown to possess both a nuclear localization signal (NLS) and a nuclear retention domain 24 , allowing it to translocate to the nucleus autonomously. Once in the nucleus, Arc has access to several other potential binding partners, including a nuclear spectrin isoform (βSpectrinIV∑5) 20 and TIP60, a subunit of a chromosome remodeling complex 25 . Association with Amida, encoded by the Tfpt gene ( Fig. 13B) facilitates Arc's entry into the nucleus 191 . Amida is a subunit of the INO80 chromatin remodeling complex, which contains the transcriptional regulator MCRS1 192, 193 . MCRS2, an isoform of MCRS1, is associated with the MLL chromatin remodeling complex, which also contains KMT2A (MLL1) ( Fig.  13B) . Arc's association with Amida and possibly the INO80 and MLL complexes may provide Arc with yet another opportunity to control gene expression by altering chromatin structure.
The ability of Arc to translocate between the synapse and the nucleus, with unique functions in each subcellular compartment, further strengthens its role in memory consolidation, which requires both alterations of synaptic function and de novo gene transcription 194 .
Arc controls synaptic plasticity and intrinsic excitability.
Arc's well-studied ability to alter synaptic efficacy by endocytosis of AMPA receptors established it as a critical regulator of synaptic plasticity 14, 17, 188, 195 . Whereas this mechanism of activity-dependent removal of glutamate receptors supports Arc's role in mediating long-term depression (LTD) [196] [197] [198] [199] , it does not explain the absence of stable long-term potentiation (LTP) observed in Arc knock-out mice 4 . Because late-LTP is considered a critical cellular mechanism underlying memory consolidation, the molecular and cellular mechanism by which Arc supports memory stabilization has remained elusive. The data presented here showing that Arc transcriptionally regulates the expression of a large number of synaptic proteins, with functions in both the pre-and post-synaptic compartment ( Table 2) , provides a new mechanism by which Arc can control long-lasting changes in synaptic structure and function required for memory consolidation.
Formation of a memory trace not only requires longterm changes in the strength of the synapses connecting the neurons that constitute the engram, but also stable changes in their intrinsic excitability [200] [201] [202] . Because Arc controls the expression of a large number of ion channels and pumps/transporters, it appears that Arc is capable of supporting this functional aspect of memory consolidation as well.
Arc and Alzheimer's disease. Alzheimer's Disease (AD) is a devastating neurodegenerative disorder 203, 204 characterized by the progressive loss of both synaptic function 205 and long-term memory formation 206 . There is currently no therapy that prevents, stabilizes or reverses the progression of this disease, which is projected to take on epidemic proportions as the world population ages 207, 208 . Several previous studies have revealed an association between Arc and AD. A landmark study published in 2011 showed that Arc protein is required for the formation of amyloid (Aβ) plaques 80 . Moreover, Arc protein levels are aberrantly regulated in the hippocampus of AD patients 209 , and are locally upregulated around amyloid plaques 210 , whereas a polymorphism in the Arc gene confers a decreased likelihood of developing AD 211 . It has been shown that spatial memory impairment is associated with dysfunctional Arc expression in the hippocampus of an AD mouse model 212 . These published results together with the data presented here, suggests that aberrant expression or dysfunction of Arc contributes to the pathophysiology of AD 205, 213 .
Arc and AD therapy. Arc's ability to transcriptionally regulate AD susceptibility and AD pathophysiology related genes indicates a possibility for modifying expression and activity of Arc as a therapy for AD. Current treatments are symptomatic, not effective disease-modifying cures 214 . Many hypotheses have been proposed to underlie the development of AD, including i) amyloid beta aggregation, ii) tau hyperphosphorylation, iii) neuroinflammation, iv) neurotransmitter dysfunction, v) mitochondria dysfunction, vi) glucose metabolism, vii) vascular dysfunction and viii) viral infection [214] [215] [216] [217] . These hypotheses have generated many new compounds, none of which showed efficacy in slowing cognitive decline or improving global functioning 214, 216 . Arc appears a good therapeutic candidate for AD, because of its involvement in amyloid beta production, tau phosphorylation, neuroinflammation and neurotransmission. Moreover, we have shown that Arc can modulate the expression of many AD genetic risk factors and genes associated with the pathophysiology of AD ( Fig. 9, Fig. 10, Fig.  12 and Table 4 ). Currently, known drugs that could increase mRNA or protein expression of Arc include antidepressant drugs 218 , phencyclidine 219 and corticosterone, a memory enhancing drug 220 . Arc expression could be altered by targeting TIP60 and PHF8, two histone modifiers that together control Arc transcription 22 . Drugs could also modulate Arc's effect via its interactors such as TIP60 and NOTCH1. Natural and synthetic drug molecules targeting TIP60 exist, but they are currently used for cancer treatment 221 . Modulation of NOTCH1 function often involves inhibitors of γ-secretase, which would also affect APP cleavage 185, 222 . These pharmaceutical modifications of Arc expression and activity could present a promising starting point for development of a more effective AD therapy.
METHODS

Animals and chemicals.
All work involving the use of animals were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) and were approved by the IACUC at the SingHealth in Singapore. Timemated E18 Sprague Dawley rats were purchased through the SingHealth Experimental Medicine Centre (SEMC). They were sacrificed immediately after delivery to the vivarium. All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Culturing hippocampal and cortical neurons. Hippocampal and cortices were dissected from the E18 embryos of Sprague Dawley rats. Hippocampi or cortices underwent papain dissociation based on the protocol from the Papain Dissociation System (Worthington Biochemical Corporation). Gentle mechanical trituration was performed to ensure complete dissociation of tissues. Dissociated cells were plated on poly-D-lysine (Sigma) coated dishes at a plating density of 1.5 x 10 5 /cm 2 in Neurobasal medium (Gibco) supplemented with 10% (v/v) foetal-bovine serum (FBS, Sigma), 1% (v/v), penicillin-streptomycin (P/S, Gibco) and 2% (v/v) B27 supplement (Gibco) for 2 hours. FBS-containing medium was then removed and replaced with FBS-free medium and cells were cultured FBSfree subsequently to prevent astrocytic over-growth. Medium was changed on Days In Vitro (DIV) 5. Subsequently, medium was changed every three to four days. Experiments were carried out on DIV 18-22.
Inhibition of Arc expression by an shRNA. Four Arc shRNA plasmids (SureSilencing, Qiagen) were transfected into neuronal cultures using Lipofectamine 2000 (Qiagen). Pharmacological LTP was induced in neuronal cell cultures using a 4-hr treatment with 4BF. Cells were fixed and stained for Arc protein. Immunofluorescence images were obtained using widefield microscopy. Effectiveness of inhibition of Arc expression was based on co-occurrence of expression of the plasmids and the absence of Arc immunofluorescence. The most effective shRNA plasmid was chosen and adeno-associated virus AAV9 constructs harbouring an Arc shRNA and a scrambled version of this shRNA were synthesized using the annealed oligo cloning method. The oligos for the Arc shRNA were: i) 5'-GAT CCG GAG GAG ATC ATT CAG T-3', ii) 5'-ATG TCT TCC TGT CAA CAT ACT GAA TGA TCT CCT CCT TTT TG-3', iii) 5'-AAT TCA AAA AGG AGG AGA TCA TTC AGT-3' and iv) 5'-ATG TTG ACA GGA AGA CAT ACT GAA TGA TCT CCT CCG-3'. The oligos for Arc scrambled shRNA were i) 5'-GAT CCG GTA ATT TCG GAG GAT C-3', ii) 5'-AAG TCT TCC TGT CAA CTT GAT CCT CCG AAA TTA CCT TTT TG-3', iii) 5'-AAT TCA AAA AGG TAA TTT CGG AGG ATC-3' and iv) 5'-AAG TTG ACA GGA AGA CTT GAT CCT CCG AAA TTA CCG-3'. The ends of the annealed oligos harbor overhangs of the restriction sites for BamH1 and EcoR1. Oligos for the Arc shRNA were annealed in buffer A (mM) 100 NaCl and 50 HEPES, pH 7.4 while oligos for Arc scrambled shRNA were annealed in buffer B (mM) 10 Tris, pH 7.5-8.0, 50 NaCl and 1 EDTA at equimolar concentration by heating to a temperature of 95°C for 5 min then cooling it down to room temperature (rtp). The annealed oligos were ligated using T4 ligase (New England Biolabs) into the BamH1/EcoR1-cut vector pENN.AAV.U6.shRLuc.CMV.eGFP.SV40, generously provided by the University of Pennsylvania, Vector Core. Ligated products were transformed into Stbl3 competent cells (Thermo Fisher Scientific). Successful constructs were identified by restriction enzymes digestion and verified by sequencing. AAV9 virus harbouring the transgenes (concentrations at 1 x 10 13 -1 x 10 14 GC/ml range) were synthesized by University of Pennsylvania, Vector Core. Arc expression was prevented by treating neuronal cultures with 3 x 10 6 multiplicity of infection (MOI) AAV9 Arc shRNA virus on DIV14. Induction of Arc expression by pharmacological LTP (see below) was performed between DIV19-22.
Pharmacological LTP and immunofluorescence. Hippocampal or cortical neuronal cultures were treated with a combination of 100 µM 4-aminopyridine (4AP), 50 µM bicuculline (Bic) and 50 µM forskolin for the respective time stated to induce pharmacological LTP 21,32,33 . This drug combination will be referred to as 4BF henceforth. At the end of the treatment, cells were fixed with 100 % ice-cold methanol at -20°C for 10 min. Cells were washed three times with 1x Phosphate Buffered Saline (PBS, in mM: 137 NaCl, 2.7 KCl and 12 phosphate buffer) containing 0.1% (v/v) Triton X-100 (PBS-Tx). Depending on the antibodies used, some cells were fixed again with 4% (w/v) paraformaldehyde (PFA) in 1x PBS containing 4% (w/v) sucrose. Cells were washed three times in 1x PBS-Tx and blocked in 2% (w/v) Bovine Serum Albumin (BSA) in 1x PBS for 1 h at rtp. Depending on the species the secondary antibodies were raised in, 10% (v/v) serum of the corresponding species was added to the blocking buffer. Cells were probed with primary antibodies as indicated for the experiments: i) anti-Arc (1:300, Santa Cruz, sc-17839), ii) anti-Arc (1:300, Synaptic Systems, 156 003), iii) anti-MAP2 (1:300, Millipore, AB5622), iv) anti-H3K27Ac (1:300, Wako, and v) anti-H3K9Ac-S10P (1:300, Abcam, ab12181) in antibody dilution buffer (1x PBS containing 1% (w/v) BSA, 5% (v/v) serum and 0.05% (v/v) Triton X-100) for 1 h at rtp. Cells were washed three times in 1x PBS-Tx. Cells were then probed with 1:1000 Alexa-Fluor 647, Alexa Fluor 568 or Alex-Fluor 488 (Molecular Probes) for 1 h at rtp. Cells were washed three times, followed by staining of DNA with 50 µM DAPI for 20 min at rtp. Cells were mounted in FluorSave (Calbiochem). For immunofluorescence staining for STORM imaging, cells were fixed with 3% paraformaldehyde and quenched with 0.1% NaBH4 as described in Oey et al. (2015) 22 . Blocking, primary and secondary antibody staining were carried out as above. A post-fixation, as described in Oey et al. (2015) 22 , was also carried out after secondary antibody binding.
Transfection of neuronal cultures. The Arc-eYFP construct was generated as described in Bloomer et al. (2007) 20 .
Neuronal cultures (DIV16) were transfected with Arc-eYFP and H2B-mCherry (Addgene, 20972) with Lipofectamine 2000 (Invitrogen) according to manufacturer's protocol with some adjustment. Arc-eYFP:H2B-mCherry DNA was added to Lipofectamine at a ratio of 1:1. The Lipofectamine:DNA complex was incubated at rtp for 20 min before been added to the cells. The complex was added dropwise such that it was evenly distributed on the cell culture. Culture medium was added after 20 min and experiments were performed on DIV19.
Widefield microscopy. Fluorescence images were obtained using widefield microscopy as detailed in Oey et al. (2015) 22 . Images obtained were analyzed using NIS Elements AR version 4.1 (Nikon) to perform background subtraction. Out-offocus fluorescence was removed using 3D deconvolution (Au-toQuant, Media Cybernetics). The Region-Of-Interest (ROI) analysis tool was used to mark nuclei based on DAPI intensity. Corresponding mean Arc intensity of each nucleus was also measured using the automated measurement module. The average of mean Arc intensity for all neurons from non-4BF stimulated controls were obtained for each set of experiments. This would be used as a cut-off threshold between Arc-positive and Arc-negative neurons for each set of experiments since Arc expression was only observed upon stimulation 223, 224 . Nuclei images were cropped individually and analyzed using a custom MATLAB (Mathworks) program. Size and intensity thresholds were applied to identify and quantitate puncta in each nucleus. Batch processing using the same size and intensity threshold was performed. Mean size of the puncta and number of puncta were recorded. ROI ID for each nucleus was used to correlate the mean Arc intensity with the mean area or number of puncta. Statistical analysis was performed using GraphPad Prism Version 6.01. Statistical data shown are mean ± S.E.M. (standard error of the mean) across experiments.
Spinning Disc confocal microscopy. Fluorescence images and time-lapse movies were obtained using a motorized Ti-E inverted microscope (Nikon) with a 60X oil Plan-Apo objective (1.49 NA) and a 100X Apo-TIRF objective (1.49 NA). Spinning disk confocal microscopy was achieved using the CSU-W1 Nipkow spinning disk confocal unit (Yokogawa Electric). A sCMOS camera (Zyla, Andor) was used to capture the confocal images. Laser lines used were 488 nm (100 mW) for GFP, 515 nm (100 mW) for eYFP and 561 nm (150 mW) for mCherry (Cube lasers, Coherent). Fast excitation/emission switching was obtained using a dichroic beam splitter (Di01-T405/488/568/647-13 x 15 x 0.5, Semrock) and filter wheels controlled by a MAC6000DC (Ludl). The Perfect Focus System (Nikon) was applied to ensure minimal focus drift during image acquisition. Z stacks were obtained using step sizes recommended for objectives used, which were processed using 3D blind deconvolution (AutoQuant) to remove out-of-focus fluorescence.
Stochastic Optical Reconstruction Microscopy (STORM).
Dual color STORM image sequences were obtained using a Zeiss ELYRA PS.1 platform. Endogenous Arc and the dual histone marker H3K9Ac-S10P were labeled with primary antibodies and visualized using Alexa 488 and Alexa 647 secondary antibodies. Time-lapse movies of 10,000 frames were obtained of neuronal nuclei expressing Arc capturing the blinking of individual Alexa 488 and 647 molecules brought into the dark state by intense laser illumination. Fitting of a 2D Gaussian to each blinking dot allowed their XY localization to be determined with high precision (typically 30 nm). Super resolution images are generated from the localizations by superimposing a 2D Gaussian (green for 488 nm, red for 647 nm) for each localized position. Molecule localization and image rendering were performed by Zen software (Zeiss).
Cell lysate preparation and Western blotting. Following 4BF stimulation, neuronal cultures were washed gently with 1x PBS. Cells were gently scraped off and harvested in an Eppendorf tube. Cells were spun down at 10000 g for 5 min at 4°C to obtain the cell pellet. Total protein was isolated using an RNA-protein extraction kit (Macherey-Nagel), as specified by the manufacturer. A BCA kit (Pierce) was used to measure the concentration of proteins. 30 µg of each protein sample was denatured and reduced by boiling at 95°C for 5 min in 10% (v/v) 2-mercaptoethanol-containing Laemmli sample buffer (Bio-Rad). Samples were resolved by SDS-PAGE with a precast Tris-glycine gel (Bio-Rad) and transferred onto PVDF membranes using the Trans-Blot Turbo transfer System (Bio-Rad) as indicated by manufacturer. Membranes were blocked for 1 h at rtp with 5% (w/v) non-fat milk block (Bio-Rad) in 1x TBS (in mM) (140 NaCl, 3 KCl, 25 Tris base) (First Base) containing 0.1% (v/v) Tween-20 (TBST), followed by primary antibodies incubation for 1 h (anti-Arc, 1:1000, Santa Cruz, sc-17839) in 1x TBST at rtp. Membranes were washed three times, each for 5 min in 1x TBST at rtp. Secondary antibodies binding was performed using the corresponding HRP-conjugated secondary (1:10000, Invitrogen) for 1 h in 1x TBST at rtp. Protein bands were detected with chemiluminescence substrate (Pierce) visualized with a Gel Doc XRS imaging system (Bio-RAD) or developed on scientific imaging film (Kodak).
RNA sample preparation, library construction, RNA-Seq and analysis. 4BF treated neuronal cells were washed, scraped and spun down as above. RNA samples were obtained from the cell pellet using the RNA-protein extraction kit as specified by manufacturer (Macherey-Nagel). Library construction and RNA sequencing were performed by the Duke-NUS Genome Biology Facility. 2.2 µg of RNA was used for library construction. Prior to library construction, quality of the RNA was analyzed with an Agilent Bioanalyzer. Following poly-A enrichment, recovered RNA was processed using the Illumina TruSeq stranded mRNA kit to generate the adaptor-ligated libraries. A total of 9 samples were analyzed. These samples Computational analyses of RNA-Seq data. FASTQ files obtained from the RNA-sequencing were mapped to the rat genome using Partek Flow (version 7.0.18.1210). Adapter sequences were trimmed. Contaminant reads contributed from rDNA, tRNA and mtDNA were filtered out using Bowtie2 (version 2.2.5). Filtered, trimmed reads of high quality (Phred score > 30) were then mapped onto the Rattus norvegicus genome (rn6) for the rat samples or Homo sapiens genome (hg38) for the HEK293T samples with Star (version 2.5.3a) 225 . Post alignment QA/QC were performed after the alignment step to determine if alignment had a good average coverage and were uniquely aligned. The unique, paired reads were used for gene expression quantification. Reads were assigned to genes using the Expectation/ Maximization (E/M) algorithm in Partek Flow 226 based on the annotation model rn6 (Ensembl transcripts release 93) for the rat samples and the annotation model hg38 (Ensembl transcripts release 94) for the HEK293 samples. To ensure only informative genes were included in the downstream analysis, noise (maximum feature counts ≤ 30) was filtered out. Read counts between samples were normalized with the Upper quantile method 227 . As genes with very low expression might be inadequately represented and incorrectly identified as differentially expressed, a constant of 1 was added to normalized counts for rectification. Statistical analysis was performed using the Gene Specific Analysis (GSA) module in Partek Flow to identify differential gene expression. P-value and fold changes of differentially expressed genes were calculated based on the lognormal with shrinkage distribution. Average coverage of less than 3 were also filtered out prior to statistical analysis. Differential gene expression with a cut-off value of false discovery rate (FDR) step-up < 0.05 228 and an absolute fold change ≥ 2 were considered for further gene ontology analysis in Partek Flow that is based on the GO Consortium (version 2018_08_01) 229, 230 . GO analysis was also performed on the transcriptional regulators/factors that were observed to be altered upon Arc knockdown using DAVID (version 6.8) 81, 231 . The EASE score obtained from the DAVID analysis is a modified Fisher Exact P-value to indicate gene enrichment in the annotation terms. Functional analysis on the statistically significant differential gene expression (FDR stepup < 0.05; absolute fold change ≥ 2) was performed by Ingenuity Pathway Analysis (IPA) ( https://tinyurl.com/y6672c22 , Qiagen). Pathways and their associated downstream effects, diseases, regulator networks and upstream regulators were identified by IPA. Predictions on the possible activation and inhibition of pathways, downstream effects and upstream regulators were inferred from the degree of consistency in the expression of the target genes compared to the fold changes in the differentially expressed gene list. This activation or inhibition status was expressed as a z-score, with z ≥ 2 indicating activation and z ≤ 2 indicating inhibition. Inferences made were based on at least one publication or from canonical information stored in the Ingenuity Knowledge Base. Fisher's exact test was used to calculate the P-value for all analyses in IPA.
Plasmid construction for Arc expression in HEK293T cells.
The following plasmids were used: pSBbi-Hyg (Addgene #60524) and pSBbi-Pur (Addgene #60523) were a gift from Eric Kowarz. pCMV(CAT)T7-SB100 (Addgene #34879) was a gift from Zsuzsanna Izsvak. sgRNA(MS2) cloning backbone plasmid, (Addgene #61424), MS2-P65-HSF1_GFP, (Addgene #61423), and dCAS9-VP64_GFP (Addgene #61422) were a gift from Feng Zhang. The psBbi-Hyg-dCAS9-VP64 and the pSBbi-MS2-P65-HSF1-Pur plasmids were constructed by isolating the dCAS9-VP64 and MS2-P65-HSF1 sequences via PCR from the MS2-P65-HSF1_GFP and dCAS9-VP64_GFP plasmids and annealed into the SfiI-linearised pSBbi-Hyg and pSBbi-Pur plasmids. psBbi-Hyg-dCAS9-VP64 and pSBbi-MS2-P65-HSF1-Pur were then co-transfected with pCMV(CAT)T7-SB100 into HEK293T using JetPrime (Polyplus-Transfection) according to manufacturer's instructions. HEK293T cells with successful transposition of both genes were selected with a combination of 0.75ug/ml puromycin (Gibco) and 200ug/ml hygromycin B (Nacalai) in DMEM + 10% FBS (Gibco) over several passages for a month.
Transfection for endogenous Arc overexpression and purification of mRNA. sgRNA(MS2) backbone plasmids containing guide RNAs complementary to human Arc promoters were transfected into the mutated HEK293T cells. A separate control well was transfected with sgRNA(MS2) backbone containing LacZ promoter sgRNAs. After 48 hours, mRNA was purified using the NucleoSpin RNA kit (Macherey-Nagel) and submitted for RNA-sequencing by the Duke-NUS Genomics Core Facility. The table below lists the guide RNAs (sgRNAs) used:
Promoter
SgRNA sequence Human Arc (1) GGGCGCTGGCGGG-GAGCCTG Human Arc (2 [345] [346] [347] . Table 3 . Prevention of activity-dependent expression of Arc resulted in gene expression profile changes that are associated with neurological diseases and psychological disorders, including Alzheimer's disease. 
